| Consensus Statement | Quality of Evidence | Strength of Rec. | Key Ref |
|---|---|---|---|
| 1. Patients with hormone receptor–positive (HR+), HER2‑positive metastatic breast cancer who have achieved disease control after first‑line induction therapy (6-8 cycles of taxane/trastuzumab/pertuzumab) should continue trastuzumab/pertuzumab (IV or SC) plus endocrine maintenance therapy and consider the addition of palbociclib | I | A | 1 |
| 2. Patients with HER2‑positive metastatic breast cancer who have achieved disease control after first‑line induction therapy (taxane/trastuzumab/pertuzumab) should continue trastuzumab/pertuzumab (IV or SC) maintenance therapy and consider the addition of tucatinib | I | A | 2 |
- Metzger O et al. N Engl J Med. 2026 Jan 29;394(5):451-462. (Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer | New England Journal of Medicine)
- Dieras V, et al. J Clin Oncol. 2025 Dec 10:JCO2502600. (HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer | Journal of Clinical Oncology)